

## Curriculum in Cardiology

### 102 Surgical Timing in Infective Endocarditis Complicated by Intracranial Hemorrhage

Rachael A. Venn, MD, MingMing Ning, MD, MMSc, Gus J. Vlahakes, MD, and Jason H. Wasfy, MD, Mphil

## Trial Designs

### 74 Expanding Opportunities to Understand Quality and Outcomes of Peripheral Vascular Interventions: The ACC NCDR PVI Registry

W. Schuyler Jones, MD, Kevin F. Kennedy, PhD, Beau M. Hawkins, MD, Robert R. Attaran, MBChB, Eric A. Secemsky, MD, MSc, Faisal Latif, MD, Nicolas W. Shammass, MD, MS, Dmitriy N. Feldman, MD, Herbert D. Aronow, MD, MPH, Bruce Gray, MD, Ehrin J. Armstrong, MD, MSc, P. Michael Grossman, MD, Kalon K.L. Ho, MD, MSc, Anand Prasad, MD, Michael R. Jaff, DO, Kenneth Rosenfield, MD, and Thomas T. Tsai, MD, Durham, NC; Kansas City, MO; Oklahoma City, OK; New Haven, CT; Boston, Newton MA; Davenport, IA; New York, NY; Providence, RI; Greenville, SC; Aurora, CO; Ann Arbor, MI; San Antonio, TX; and Denver, CO

### 82 The OPTIMIZE Randomized Trial to Assess Safety and Efficacy of the Svelte IDS and RX Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Trial Design and Rationale

Laura Mauri, MD, MSc, Gheorghe Doros, PhD, Sunil V. Rao, MD, David J. Cohen, MD, MSc, Steven Yakubov, MD, John Lasala, MD, PhD, S. Chiu Wong, MD, James Zidar, MD, and Dean J. Kereiakes, MD

### 91 Rationale and Design of a Nurse-Led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention Trial (EXTRA-CVD)

Nwora Lance Okeke, Allison R. Weibel, Hayden B. Bosworth, Angela Aifah, Gerald S. Bloomfield, Emily W. Choi, Sarah Gonzales, Sarah Hale, Corri Lynn O. Hileman, Virginie Lopez-Kidwell, Charles Muiruri, Megan Oakes, Julie Schexnayder, Valerie Smith, Rajesh Vedanthan, and Chris T. Longenecker

## Clinical Investigations

### 1 The Prevalence of Atrial Fibrillation on 48-Hour Ambulatory Electrocardiography in African Americans Compared to Whites: The Atherosclerosis Risk in Communities (ARIC) Study

Laura R. Loehr, MD, PhD, Elsayed Z. Soliman, MD, Anna K. Poon, MS, David Couper, PhD, Lin Yee Chen, MD, MS, Thomas H. Mosley, PhD, Lynne E. Wagenknecht, PhD, Eric A. Whitsett, MD, Alvaro Alonso, MD, PhD, Lisa Wruck, PhD, and Gerardo Heiss, MD, PhD, Chapel Hill, Winston Salem, Durham, NC; Minneapolis, MN; Jackson, MS; and Atlanta, GA

### 9 Cardiovascular Risk Factor Reduction by Community Health Workers In Rural India: A Cluster Randomized Trial

Rajnish Joshi, MD, MPH, PhD, Twinkle Agrawal, MD, Farah Fathima, MD, Thammattoor Usha, MSc, Tinku Thomas, MSc, PhD, Dominic Misquith, MD, Shriprakash Kalantri, MD, MPH, Natesan Chidambaram, MD, Tony Raj, MD, Alben Singamani, MD, Shailendra Hegde, MD, Denis Xavier, MD, MSc, PJ Devereaux, MD, Prem Pais, MD, Rajeev Gupta, MD, PhD, and Salim Yusuf, MBBS, Dphil, Bhopal, India; Bangalore, India; Sevagram, India; Annamalainagar, India; Narayana Health Bangalore, India; Tamil Nadu, India; Ontario, Canada; and Jaipur, India

- 20** High-Sensitivity C-Reactive Protein and the Risk of Chronic Kidney Disease Progression or Acute Kidney Injury in Post-Myocardial Infarction Patients  
*Edouard L. Fu, BS, Mikael Andersson Franko, PhD, Achim Oberfell, MD, PhD, Friedo W. Dekker, PhD, Anders Gabrielsen, MD, PhD, Tomas Jernberg, MD, PhD, and Juan Jesús Carrero, PharmD, PhD, Leiden, the Netherlands; Stockholm, Sweden; Novartis Pharma AG, Basel, Switzerland*
- 30** Simulation of Impact on Cardiovascular Events Due to Lipid-Lowering Therapy Intensification in a Population with Atherosclerotic Cardiovascular Disease  
*Christopher P. Cannon, MD, Irfan Khan, PhD, Alexa C. Klimchak, MS, Robert J. Sanchez, PhD, William J. Sasiela, PhD, Joseph M. Massaro, PhD, Ralph B. D'Agostino, Sr., PhD, and Matthew R. Reynolds, MD, Msc, Boston, MA; Bridgewater, NJ; Berkeley Heights, NJ; and Tarrytown, NY*
- 42** Amyloid Cardiomyopathy in a Large Integrated Health Care System  
*Peter Czobor, MD, Yun-Yi Hung, PhD, David Baer, MD, Dana McGlothlin, MD, Dana Weisshaar, MD, and Jonathan Zaroff, MD*
- 53** Ad Hoc Percutaneous Coronary Intervention in Patients with Stable Coronary Artery Disease: A Report from the National Cardiovascular Data RegistryCath PCI Registry  
*Kamil F. Faridi, MD, Jennifer A. Rymer, MD, MBA, Sunil V. Rao, MD, David Dai, PhD, Daniel Wojdyla, MS, Robert W. Yeh, MD, MSc, and Tracy Y. Wang, MD, MHS, Msc, Boston, MA and Durham, NC*
- 62** Premorbid Levels of High-Sensitivity Cardiac Troponin T and Natriuretic Peptide and Prognosis after Incident Myocardial Infarction  
*Yejin Mok, PhD, MPH, Yingying Sang, MS, Shoshana H. Ballew, PhD, Ron C. Hoogeveen, PhD, Christie M. Ballantyne, MD, Wayne Rosamond, PhD, Josef Coresh, MD, PhD, Elizabeth Selvin, PhD, MPH, and Kunihiro Matsushita, MD, PhD, MD, TX, and NC, USA*
- 117** Direct Oral Anticoagulant- Versus Vitamin K Antagonist-Related Gastrointestinal Bleeding: Insights from a Nationwide Cohort  
*Jawad H. Butt, MD, Ang Li, MD, Ying Xian, MD, PhD, Eric D. Peterson, MD, MPH, David Garcia, MD, Christian Torp-Pedersen, MD, DMSc, Lars Køber, MD, DMSc, and Emil L. Fosbøl, MD, PhD, Copenhagen, Aalborg Denmark; Seattle, WA and Durham, NC*
- 125** Abnormal Glucose Metabolism in Patients with Fontan Circulation: Unique Characteristics and Associations with Fontan Pathophysiology  
*Hideo Ohuchi, MD, PhD, Jun Negishi, MD, Yosuke Hayama, MD, Hikari Miike, MD, Dai Suzuki, MD, Kimiko Nakajima, MD, Nao Konagai, MD, Toru Iwasa, MD, Heima Sakaguchi, MD, PhD, Kenichi Kurosaki, MD, and Michikazu Nakai, PhD*
- 136** Identification, Diagnosis, Treatment, and In-hospital Outcomes of Acute Pulmonary Embolism: Results from a Single Integrated Health System  
*Tara Holder, MD, Alexander E. Sullivan, MD, Tracy Truong, MS, Manesh R. Patel, MD, Olamiji Sofela, MBChB, MMCI, Cynthia L. Green, PhD, Talal Dahhan, MD, MSED, and W. Schuyler Jones, MD, Durham, NC*

### Research Letters

- 113** High Prevalence of Cholesterol-Rich Atherosclerotic Lesions in Ancient Mummies: A Near-Infrared Spectroscopy Study  
*Mohammad Madjid, MD, MS, Payam Safavi-Naeini, MD, and Robert Lodder, PhD, Houston, TX, and KY, United States*
- 143** Temporal Evolution of Myeloperoxidase and Galectin 3 During 1 Year after Acute Coronary Syndrome Admission  
*Maxime M. Vroegindewey, MSc, Victor J. van den Berg, MD, MSc, Elke Bouwens, MD, Msc, K. Martijn Akkerhuis, MD, PhD, Rohit M. Oemrawsingh, MD, MSc, Folkert W. Asselbergs, MD, PhD, Timo Lenderink, MD, PhD, Pim van der Harst, MD, PhD, Eelco Ronner, MD, PhD, Victor A. W. M. Umans, MD, PhD, Isabella Kardys, MD, PhD, and Eric Boersma, PhD, Rotterdam, Alkmaar, Breda, Utrecht, Heerlen, Groningen, and Delft, The Netherlands*
- 147** Clinical Effects of Cyclosporine in Acute Anterior Myocardial Infarction Complicated by Heart Failure: A Subgroup Analysis of the CIRCUS Trial  
*Marc J. Claeys, MD, PhD, Patrick Coussement, MD, PhD, Philippe Dubois, MD, D. Garcia-Dorado, MD, PhD, N. Mewton, MD, PhD, C. Amaz, PhD, and M. Ovize, MD, PhD, Belgium, Spain, CIBER-CV, and France*

## Contents *continued*

### Erratum

- 150** Correction to “Sex Differences in Long-Term Outcomes of Patients Across the Spectrum of Coronary Artery Disease”, [American Heart Journal (December 2018) 51-60]
- 151** Erratum to “Increased Hepatocyte Growth Factor Levels Over 2 Years are Associated with Coronary Heart Disease: The Multi-Ethnic Study Of Atherosclerosis (MESA)” [Am Heart J (2019) 30–34]  
*Paul A. Decker, MS, Nicholas B. Larson, PhD, Elizabeth J. Bell, PhD, James S. Pankow, PhD, MPH, Naomi Q. Hanson, MS, Christina L. Wassel, PhD, Michael Y. Tsai, PhD, and Suzette J. Bielinski, PhD, Med, Rochester, Minneapolis, MN; and Charlotte, NC*